Clinical trial
Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for…
NCT00111657 · John Sundy, Other · Completed
Key facts
| NCT number | NCT00111657 |
|---|---|
| Title | Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout |
| Official title | A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout |
| Lead sponsor | John Sundy, Other |
| Collaborators | Savient Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gout |
| Intervention type | Biological |
| Interventions | Pegloticase |
| Enrollment | 30 |
| Start date | Dec 1, 2004 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | May 25, 2005 |
| Last update posted | Oct 3, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: